Skip to main content
Erschienen in: Current Infectious Disease Reports 4/2011

01.08.2011

West Nile Virus Neuroinvasive Disease

verfasst von: Roberta L. DeBiasi

Erschienen in: Current Infectious Disease Reports | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

West Nile virus (WNV), first recognized in North America in 1999, was responsible for the largest arboviral epidemic of human encephalitis in history and continues to be the most frequent cause of epidemic meningoencephalitis in North America. WNV neuroinvasive disease (WNND) occurs in fewer than 1% of infected individuals, with presentations including aseptic meningitis, encephalitis, and poliomyelitis. Between 1999 and 2009, over 12,000 cases of WNND were reported in the United States, with the peak annual incidence occurring in epidemics of 2002 and 2003. In this review, we first summarize the epidemiology of WNV over the past decade and the salient clinical features of WNND, including a discussion of laboratory and radiographic findings, risk factors, morbidity, and mortality. In addition, we review recent progress in our understanding of virus and host determinants of the pathogenesis of WNND, as well as the prospects for the development of specific therapeutic targets.
Literatur
1.
Zurück zum Zitat Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–14.PubMedCrossRef Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–14.PubMedCrossRef
2.
Zurück zum Zitat Hayes EB, Komar N, Nasci RS, et al. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11:1167–73.PubMed Hayes EB, Komar N, Nasci RS, et al. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11:1167–73.PubMed
3.
Zurück zum Zitat •• Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease - United States, 1999–2008. MMWR Surveill Summ. 2010;59(2):1–17. This is the most up-to-date summary on incidence rates for WNND over the 10-year period of WNV circulation in North America following first emergence, including incidence rates by age groups and top states for reported cases. The discussion of stability in incidence rates between 2004 and 2007 is suggestive of a potential endemic level of WNV transmission. PubMed •• Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease - United States, 1999–2008. MMWR Surveill Summ. 2010;59(2):1–17. This is the most up-to-date summary on incidence rates for WNND over the 10-year period of WNV circulation in North America following first emergence, including incidence rates by age groups and top states for reported cases. The discussion of stability in incidence rates between 2004 and 2007 is suggestive of a potential endemic level of WNV transmission. PubMed
4.
Zurück zum Zitat • Centers for Disease Control (CDC). West Nile virus activity - United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(25):769–72. This is the most up-to-date single-year summary of WNV activity (including WNND), including the lowest incidence rate since the appearance of WNV in North America. • Centers for Disease Control (CDC). West Nile virus activity - United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(25):769–72. This is the most up-to-date single-year summary of WNV activity (including WNND), including the lowest incidence rate since the appearance of WNV in North America.
5.
Zurück zum Zitat Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999–2007. Am J Trop Med Hyg. 2008;79:974–9.PubMed Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999–2007. Am J Trop Med Hyg. 2008;79:974–9.PubMed
6.
Zurück zum Zitat Schweitzer BK, Kramer WL, Sambol AR, et al. Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic. Clin Vaccine Immunol. 2006;13:314–8.PubMedCrossRef Schweitzer BK, Kramer WL, Sambol AR, et al. Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic. Clin Vaccine Immunol. 2006;13:314–8.PubMedCrossRef
7.
Zurück zum Zitat Centers for Disease Control (CDC). West Nile virus screening of blood donations and transfusion-associated transmission - United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:281–4. Centers for Disease Control (CDC). West Nile virus screening of blood donations and transfusion-associated transmission - United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:281–4.
8.
Zurück zum Zitat Petersen LR, Epstein JS. Problem solved? West Nile virus and transfusion safety. N Engl J Med. 2005;353:516–7.PubMedCrossRef Petersen LR, Epstein JS. Problem solved? West Nile virus and transfusion safety. N Engl J Med. 2005;353:516–7.PubMedCrossRef
9.
Zurück zum Zitat Centers for Disease Control (CDC). West Nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1263–7. Centers for Disease Control (CDC). West Nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1263–7.
10.
Zurück zum Zitat O’Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile virus infection of pregnant women in the United States: 2003–2004. Pediatrics. 2006;117:e537–45.PubMedCrossRef O’Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile virus infection of pregnant women in the United States: 2003–2004. Pediatrics. 2006;117:e537–45.PubMedCrossRef
11.
Zurück zum Zitat Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med. 2004;141:360–5.PubMed Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med. 2004;141:360–5.PubMed
12.
13.
Zurück zum Zitat Sejvar JJ, Marfin AA. Manifestations of West Nile neuroinvasive disease. Rev Med Virol. 2006;16:209–24.PubMedCrossRef Sejvar JJ, Marfin AA. Manifestations of West Nile neuroinvasive disease. Rev Med Virol. 2006;16:209–24.PubMedCrossRef
14.
Zurück zum Zitat Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006;57:181–94.PubMedCrossRef Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006;57:181–94.PubMedCrossRef
15.
16.
Zurück zum Zitat •• Lindsey NP, Hayes EB, Staples JE, Fischer M. West Nile virus disease in children, United States, 1999–2007. Pediatrics. 2009;123:e1084-9. This is the most comprehensive summary of pediatric cases of WNV in the United States over the 9 years following the first US appearance of WNV. PubMedCrossRef •• Lindsey NP, Hayes EB, Staples JE, Fischer M. West Nile virus disease in children, United States, 1999–2007. Pediatrics. 2009;123:e1084-9. This is the most comprehensive summary of pediatric cases of WNV in the United States over the 9 years following the first US appearance of WNV. PubMedCrossRef
17.
Zurück zum Zitat Bakri SJ, Kaiser PK. Ocular manifestations of West Nile virus. Curr Opin Ophthalmol. 2004;15:537–40.PubMedCrossRef Bakri SJ, Kaiser PK. Ocular manifestations of West Nile virus. Curr Opin Ophthalmol. 2004;15:537–40.PubMedCrossRef
18.
Zurück zum Zitat Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11:1021–7.PubMed Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11:1021–7.PubMed
19.
Zurück zum Zitat Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286–300.PubMedCrossRef Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286–300.PubMedCrossRef
20.
Zurück zum Zitat Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11:1174–9.PubMed Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11:1174–9.PubMed
21.
Zurück zum Zitat Lindsey NP, Kuhn S, Campbell GL, Hayes EB. West Nile virus neuroinvasive disease incidence in the United States, 2002–2006. Vector Borne Zoonotic Dis. 2008;8:35–9.PubMedCrossRef Lindsey NP, Kuhn S, Campbell GL, Hayes EB. West Nile virus neuroinvasive disease incidence in the United States, 2002–2006. Vector Borne Zoonotic Dis. 2008;8:35–9.PubMedCrossRef
22.
Zurück zum Zitat Caillouet KA, Michaels SR, Xiong X, et al. Increase in West Nile neuroinvasive disease after Hurricane Katrina. Emerg Infect Dis. 2008;14:804–7.PubMedCrossRef Caillouet KA, Michaels SR, Xiong X, et al. Increase in West Nile neuroinvasive disease after Hurricane Katrina. Emerg Infect Dis. 2008;14:804–7.PubMedCrossRef
23.
Zurück zum Zitat Hayes EB, O’Leary DR. West Nile virus infection: a pediatric perspective. Pediatrics. 2004;113:1375–81.PubMedCrossRef Hayes EB, O’Leary DR. West Nile virus infection: a pediatric perspective. Pediatrics. 2004;113:1375–81.PubMedCrossRef
24.
Zurück zum Zitat DeSalvo D, Roy-Chaudhury P, Peddi R, et al. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation. 2004;77:466–9.PubMedCrossRef DeSalvo D, Roy-Chaudhury P, Peddi R, et al. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation. 2004;77:466–9.PubMedCrossRef
25.
Zurück zum Zitat Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004;61:1210–20.PubMedCrossRef Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol. 2004;61:1210–20.PubMedCrossRef
26.
Zurück zum Zitat Murray K, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect. 2006;134:1325–32.PubMedCrossRef Murray K, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect. 2006;134:1325–32.PubMedCrossRef
27.
Zurück zum Zitat Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2010;24(2):223–8.PubMedCrossRef Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2010;24(2):223–8.PubMedCrossRef
28.
Zurück zum Zitat • Murray KO, Koers E, Baraniuk S, et al. Risk Factors for Encephalitis from West Nile Virus: a matched case-control study using hospitalized controls. Zoonoses Public Health 2009 Jan 17 (Epub ahead of print). This is a recent nested case-control study to determine potential risk factors for developing WNE by analysis of WNV cases hospitalized in Houston from 2002 to 2004. • Murray KO, Koers E, Baraniuk S, et al. Risk Factors for Encephalitis from West Nile Virus: a matched case-control study using hospitalized controls. Zoonoses Public Health 2009 Jan 17 (Epub ahead of print). This is a recent nested case-control study to determine potential risk factors for developing WNE by analysis of WNV cases hospitalized in Houston from 2002 to 2004.
29.
Zurück zum Zitat Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376–9.PubMed Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376–9.PubMed
30.
Zurück zum Zitat Levett PN, Sonnenberg K, Sidaway F, et al. Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol. 2005;43:5873–5.PubMedCrossRef Levett PN, Sonnenberg K, Sidaway F, et al. Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol. 2005;43:5873–5.PubMedCrossRef
31.
Zurück zum Zitat Lanciotti RS, Kerst AJ. Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol. 2001;39:4506–13.PubMedCrossRef Lanciotti RS, Kerst AJ. Nucleic acid sequence-based amplification assays for rapid detection of West Nile and St. Louis encephalitis viruses. J Clin Microbiol. 2001;39:4506–13.PubMedCrossRef
32.
Zurück zum Zitat Tyler KL, Pape J, Goody RJ, et al. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology. 2006;66:361–5.PubMedCrossRef Tyler KL, Pape J, Goody RJ, et al. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology. 2006;66:361–5.PubMedCrossRef
33.
Zurück zum Zitat Petzold A, Groves M, Leis AA, et al. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve. 2010;41:42–9.PubMedCrossRef Petzold A, Groves M, Leis AA, et al. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve. 2010;41:42–9.PubMedCrossRef
34.
Zurück zum Zitat Brilla R, Block M, Geremia G, Wichter M. Clinical and neuroradiologic features of 39 consecutive cases of West Nile Virus meningoencephalitis. J Neurol Sci. 2004;220:37–40.PubMedCrossRef Brilla R, Block M, Geremia G, Wichter M. Clinical and neuroradiologic features of 39 consecutive cases of West Nile Virus meningoencephalitis. J Neurol Sci. 2004;220:37–40.PubMedCrossRef
35.
Zurück zum Zitat Ali M, Safriel Y, Sohi J, et al. West Nile virus infection: MR imaging findings in the nervous system. AJNR Am J Neuroradiol. 2005;26:289–97.PubMed Ali M, Safriel Y, Sohi J, et al. West Nile virus infection: MR imaging findings in the nervous system. AJNR Am J Neuroradiol. 2005;26:289–97.PubMed
36.
Zurück zum Zitat Petropoulou KA, Gordon SM, Prayson RA, Ruggierri PM. West Nile virus meningoencephalitis: MR imaging findings. AJNR Am J Neuroradiol. 2005;26:1986–95.PubMed Petropoulou KA, Gordon SM, Prayson RA, Ruggierri PM. West Nile virus meningoencephalitis: MR imaging findings. AJNR Am J Neuroradiol. 2005;26:1986–95.PubMed
37.
38.
Zurück zum Zitat Blakely PK, Kleinschmidt-DeMasters BK, Tyler KL, Irani DN. Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection. J Neuropathol Exp Neurol. 2009;68:1061–72.PubMedCrossRef Blakely PK, Kleinschmidt-DeMasters BK, Tyler KL, Irani DN. Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection. J Neuropathol Exp Neurol. 2009;68:1061–72.PubMedCrossRef
39.
Zurück zum Zitat Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44:1617–24.PubMedCrossRef Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44:1617–24.PubMedCrossRef
40.
Zurück zum Zitat Murray KO, Baraniuk S, Resnick M, et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002–2004. Vector Borne Zoonotic Dis. 2008;8:167–74.PubMedCrossRef Murray KO, Baraniuk S, Resnick M, et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002–2004. Vector Borne Zoonotic Dis. 2008;8:167–74.PubMedCrossRef
41.
Zurück zum Zitat Sejvar JJ, Bode AV, Marfin AA, et al. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006;12:514–6.PubMed Sejvar JJ, Bode AV, Marfin AA, et al. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006;12:514–6.PubMed
42.
Zurück zum Zitat Sejvar JJ, Curns AT, Welburg L, et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol. 2008;2:477–99.PubMedCrossRef Sejvar JJ, Curns AT, Welburg L, et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol. 2008;2:477–99.PubMedCrossRef
43.
Zurück zum Zitat Murray KO, Resnick M, Miller V. Depression after infection with West Nile virus. Emerg Infect Dis. 2007;13:479–81.PubMedCrossRef Murray KO, Resnick M, Miller V. Depression after infection with West Nile virus. Emerg Infect Dis. 2007;13:479–81.PubMedCrossRef
44.
Zurück zum Zitat Haaland KY, Sadek J, Pergam S, et al. Mental status after West Nile virus infection. Emerg Infect Dis. 2006;12:1260–2.PubMed Haaland KY, Sadek J, Pergam S, et al. Mental status after West Nile virus infection. Emerg Infect Dis. 2006;12:1260–2.PubMed
45.
Zurück zum Zitat Sadek JR, Pergam SA, Harrington JA, et al. Persistent neuropsychological impairment associated with West Nile virus infection. J Clin Exp Neuropsychol. 2009 Jun 8:1–8 (Epub ahead of print). Sadek JR, Pergam SA, Harrington JA, et al. Persistent neuropsychological impairment associated with West Nile virus infection. J Clin Exp Neuropsychol. 2009 Jun 8:1–8 (Epub ahead of print).
46.
Zurück zum Zitat •• Diamond MS. Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog. 2009;5:e1000452. This is an up-to-date, concise review of current science providing insights into WNV and WNND pathogenesis, including host genetic factors and viral determinants. PubMedCrossRef •• Diamond MS. Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog. 2009;5:e1000452. This is an up-to-date, concise review of current science providing insights into WNV and WNND pathogenesis, including host genetic factors and viral determinants. PubMedCrossRef
47.
Zurück zum Zitat Brault AC, Huang CY, Langevin SA, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet. 2007;39:1162–6.PubMedCrossRef Brault AC, Huang CY, Langevin SA, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet. 2007;39:1162–6.PubMedCrossRef
48.
Zurück zum Zitat Moudy RM, Zhang B, Shi PY, Kramer LD. West Nile virus envelope protein glycosylation is required for efficient viral transmission by Culex vectors. Virology. 2009;387:222–8.PubMedCrossRef Moudy RM, Zhang B, Shi PY, Kramer LD. West Nile virus envelope protein glycosylation is required for efficient viral transmission by Culex vectors. Virology. 2009;387:222–8.PubMedCrossRef
49.
Zurück zum Zitat Beasley DW, Davis CT, Whiteman M, et al. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl. 2004;18:35–41.PubMed Beasley DW, Davis CT, Whiteman M, et al. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl. 2004;18:35–41.PubMed
50.
Zurück zum Zitat Wicker JA, Whiteman MC, Beasley DW, et al. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology. 2006;349:245–53.PubMedCrossRef Wicker JA, Whiteman MC, Beasley DW, et al. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology. 2006;349:245–53.PubMedCrossRef
51.
Zurück zum Zitat Samuel MA, Diamond MS. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol. 2006;80:9349–60.PubMedCrossRef Samuel MA, Diamond MS. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol. 2006;80:9349–60.PubMedCrossRef
52.
Zurück zum Zitat Piazza P, McMurtrey CP, Lelic A, et al. Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS ONE. 2010;5:e15343.PubMedCrossRef Piazza P, McMurtrey CP, Lelic A, et al. Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS ONE. 2010;5:e15343.PubMedCrossRef
53.
Zurück zum Zitat Lanteri MC, O’Brien KM, Purtha WE, et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest. 2009;119:3266–77.PubMed Lanteri MC, O’Brien KM, Purtha WE, et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest. 2009;119:3266–77.PubMed
54.
Zurück zum Zitat Mansfield KL, Johnson N, Cosby SL, et al. Transcriptional upregulation of SOCS 1 and suppressors of cytokine signaling 3 mRNA in the absence of suppressors of cytokine signaling 2 mRNA after infection with West Nile virus or tick-borne encephalitis virus. Vector Borne Zoonotic Dis. 2010;10:649–53.PubMedCrossRef Mansfield KL, Johnson N, Cosby SL, et al. Transcriptional upregulation of SOCS 1 and suppressors of cytokine signaling 3 mRNA in the absence of suppressors of cytokine signaling 2 mRNA after infection with West Nile virus or tick-borne encephalitis virus. Vector Borne Zoonotic Dis. 2010;10:649–53.PubMedCrossRef
55.
Zurück zum Zitat Kumar M, Verma S, Nerurkar VR. Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death. J Neuroinflammation. 2010;7:73.PubMedCrossRef Kumar M, Verma S, Nerurkar VR. Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death. J Neuroinflammation. 2010;7:73.PubMedCrossRef
56.
Zurück zum Zitat Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35–40.PubMedCrossRef Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35–40.PubMedCrossRef
57.
Zurück zum Zitat Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 2009;5:e1000321.PubMedCrossRef Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 2009;5:e1000321.PubMedCrossRef
58.
Zurück zum Zitat •• Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res. 2009;83:214–27. This excellent, up-to-date review describes the current state of knowledge on epidemiology, clinical presentation, pathogenesis, and immunobiology of WNV infection, with particular focus on progress toward development of effective therapies. PubMedCrossRef •• Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res. 2009;83:214–27. This excellent, up-to-date review describes the current state of knowledge on epidemiology, clinical presentation, pathogenesis, and immunobiology of WNV infection, with particular focus on progress toward development of effective therapies. PubMedCrossRef
59.
Zurück zum Zitat Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7:675–8.PubMedCrossRef Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7:675–8.PubMedCrossRef
60.
Zurück zum Zitat Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol. 2005;79:13350–61.PubMedCrossRef Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol. 2005;79:13350–61.PubMedCrossRef
61.
Zurück zum Zitat Morrey JD, Day CW, Julander JG, et al. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother. 2004;15:101–9.PubMed Morrey JD, Day CW, Julander JG, et al. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother. 2004;15:101–9.PubMed
63.
Zurück zum Zitat Ben Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188:5–12.PubMedCrossRef Ben Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis. 2003;188:5–12.PubMedCrossRef
64.
Zurück zum Zitat Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol. 2003;77:12941–9.PubMedCrossRef Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol. 2003;77:12941–9.PubMedCrossRef
65.
Zurück zum Zitat Morrey JD, Siddharthan V, Wang H, et al. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol. 2008;14:152–63.PubMedCrossRef Morrey JD, Siddharthan V, Wang H, et al. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol. 2008;14:152–63.PubMedCrossRef
66.
Zurück zum Zitat Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005;11:522–30.PubMedCrossRef Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005;11:522–30.PubMedCrossRef
67.
Zurück zum Zitat Thompson BS, Moesker B, Smit JM, et al. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog. 2009;5:e1000453.PubMedCrossRef Thompson BS, Moesker B, Smit JM, et al. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog. 2009;5:e1000453.PubMedCrossRef
68.
Zurück zum Zitat Vogt MR, Moesker B, Goudsmit J, et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol. 2009;83:6494–507.PubMedCrossRef Vogt MR, Moesker B, Goudsmit J, et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol. 2009;83:6494–507.PubMedCrossRef
69.
Zurück zum Zitat Zhang S, Vogt MR, Oliphant T, et al. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis. 2009;200:202–5.PubMedCrossRef Zhang S, Vogt MR, Oliphant T, et al. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis. 2009;200:202–5.PubMedCrossRef
70.
Zurück zum Zitat Lai H, Engle M, Fuchs A, et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci USA. 2010;107:2419–24. Lai H, Engle M, Fuchs A, et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci USA. 2010;107:2419–24.
71.
Zurück zum Zitat Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol. 2005;79:4599–609.PubMedCrossRef Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol. 2005;79:4599–609.PubMedCrossRef
72.
Zurück zum Zitat Bai F, Wang T, Pal U, et al. Use of RNA interference to prevent lethal murine west nile virus infection. J Infect Dis. 2005;191:1148–54.PubMedCrossRef Bai F, Wang T, Pal U, et al. Use of RNA interference to prevent lethal murine west nile virus infection. J Infect Dis. 2005;191:1148–54.PubMedCrossRef
73.
Zurück zum Zitat Bai F, Town T, Pradhan D, et al. Antiviral peptides targeting the west nile virus envelope protein. J Virol. 2007;81:2047–55.PubMedCrossRef Bai F, Town T, Pradhan D, et al. Antiviral peptides targeting the west nile virus envelope protein. J Virol. 2007;81:2047–55.PubMedCrossRef
74.
Zurück zum Zitat Chang J, Wang L, Ma D, et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother. 2009;53:1501–8.PubMedCrossRef Chang J, Wang L, Ma D, et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother. 2009;53:1501–8.PubMedCrossRef
Metadaten
Titel
West Nile Virus Neuroinvasive Disease
verfasst von
Roberta L. DeBiasi
Publikationsdatum
01.08.2011
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 4/2011
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0193-9

Weitere Artikel der Ausgabe 4/2011

Current Infectious Disease Reports 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.